<div id="readability-page-1"><div><p>Danish pharmaceutical company Genmab has finalized its offer for all outstanding common shares in Merus. With this acquisition, the drug candidate petosemtamab, which holds two Breakthrough Therapy Designations, is now part of Genmab's portfolio.</p><p>  Genmab anticipates that petosemtamab will have a positive impact on EBITDA, projecting an annual sales potential of at least $1 billion through 2029, and subsequently, an annual revenue potential in the multi-billion dollar range.</p><p>  &#34;We are energized by the potential of petosemtamab to make a difference for patients with head and neck cancer,&#34; said CEO Jan van de Winkel in a press release.</p><p>Genmab now controls a total of 94.2 percent of Merus and has decided to give shareholders another opportunity to accept the offer by extending the acceptance period by ten trading days, until December 29. The offered price remains at $97 per share.</p></div></div>

MRUS

GMAB

<p>Genmab 已完成對 Merus 的收購，將癌症治療藥物 petosemtamab 納入其產品組合。petosemtamab 獲得了兩個突破性療法認證，預計將對 EBITDA 產生積極影響，並在 2029 年前實現至少 10 億美元的年銷售額。Genmab 現在控制了 Merus 的 94.2%，並將要約接受期限延長至 12 月 29 日，維持每股 97 美元的價格</p>

Genmab 完成對 Merus 的收購，藉助新的癌症治療方案增強其產品組合